Hancock Jaffe Laboratories, Inc.: directors' dealings · United States · SEC (Form 4)

About Hancock Jaffe Laboratories, Inc.

Hancock Jaffe Laboratories, Inc. is a United States medical device company that was quoted on NASDAQ (United States) under the HJLI ticker during the period reflected in its SEC filings and company communications. Based on its SEC reporting, the company’s core identity has been that of a development-stage medtech business focused on tissue-based solutions for cardiovascular, venous, and peripheral arterial disease. For investors, the key takeaway is that Hancock Jaffe has historically been a clinical and regulatory execution story rather than a mature commercial-device platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1661053/000149315221007526/form10-k.htm?utm_source=openai)) The company’s origins go back to the late 1990s according to its historical disclosures and press materials, and it has emphasized a long operating history in bioprosthetic and tissue-based medical devices. Its management team has also highlighted experience associated with a broad base of FDA-cleared or CE-marked products, which matters in a sector where prior regulatory execution can improve credibility with physicians, regulators, and capital markets. This history supports a narrative of technical specialization in regenerative and implantable vascular technologies rather than a diversified device portfolio. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1661053/000149315221007526/form10-k.htm?utm_source=openai)) Hancock Jaffe’s principal programs have centered on two lead product candidates. VenoValve is a porcine-based device intended for surgical implantation in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency, a condition that can become highly debilitating in advanced cases. CoreoGraft is a bovine tissue-based, off-the-shelf conduit intended for coronary artery bypass graft procedures. Together, these programs target large but specialized cardiovascular markets where a clinically effective tissue-based alternative could address unmet need and potentially offer differentiation versus existing surgical options. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1661053/000149315221007526/form10-k.htm?utm_source=openai)) Operationally, the company disclosed a 14,507-square-foot manufacturing facility in Irvine, California, used for clinical-trial production and previously certified by the FDA for commercial device manufacturing. That footprint is meaningful for a small-cap medtech company because it provides in-house manufacturing capability, product iteration support, and a platform for future scale-up if clinical and regulatory milestones are achieved. At the same time, the business profile remained highly dependent on external financing, clinical development, and regulatory outcomes. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1661053/000149315221007526/form10-k.htm?utm_source=openai)) Recent company milestones included Nasdaq compliance-related announcements and a 2021 disclosure that Hancock Jaffe would change its name to enVVeno Medical Corporation with a new ticker, indicating a corporate transition that investors should consider when mapping legacy HJLI filings to the current entity structure. The company also completed equity financing during this period, underscoring the capital-intensive nature of its development roadmap. For an investor looking at SEC Form 4 insider transactions, the most relevant context is that this is a high-risk, innovation-led medtech company whose valuation has historically been driven by regulatory progress, financing events, and trial-readout expectations rather than current product revenue. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1661053/000149315221023320/ex99-1.htm?utm_source=openai))